CALR and benign prostatic hyperplasia: After injection with 50 nL (5 μg/μL) dsRNA-calreticulin and dsRNA-cathepsin-B of BPH, maximal reduction values of calreticulin and cathepsin-B were reported as 43.8% and 36.4%, respectively33.